CRIS Current Research Information System

COSMI, BENILDE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.165
AS - Asia 5.740
EU - Europa 4.163
SA - Sud America 323
AF - Africa 289
OC - Oceania 43
Continente sconosciuto - Info sul continente non disponibili 2
Totale 17.725
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.083
SG - Singapore 2.185
CN - Cina 1.670
GB - Regno Unito 1.219
VN - Vietnam 669
DE - Germania 654
IT - Italia 561
HK - Hong Kong 446
SE - Svezia 366
IN - India 319
RU - Federazione Russa 298
BR - Brasile 228
UA - Ucraina 210
FR - Francia 204
IE - Irlanda 172
KR - Corea 170
NL - Olanda 147
ZA - Sudafrica 109
EE - Estonia 92
JP - Giappone 85
SC - Seychelles 57
CI - Costa d'Avorio 53
FI - Finlandia 51
AR - Argentina 49
ID - Indonesia 47
AT - Austria 37
CA - Canada 35
MX - Messico 34
AU - Australia 31
BE - Belgio 25
CH - Svizzera 24
EG - Egitto 22
CZ - Repubblica Ceca 21
IQ - Iraq 19
JO - Giordania 18
PH - Filippine 18
GR - Grecia 17
PL - Polonia 17
TG - Togo 14
TW - Taiwan 12
BD - Bangladesh 11
NZ - Nuova Zelanda 11
MA - Marocco 10
PK - Pakistan 10
BG - Bulgaria 9
CL - Cile 9
EC - Ecuador 9
ES - Italia 9
MY - Malesia 9
TR - Turchia 9
RO - Romania 8
TH - Thailandia 8
PE - Perù 7
UZ - Uzbekistan 7
CO - Colombia 6
LB - Libano 6
SA - Arabia Saudita 6
UY - Uruguay 6
DZ - Algeria 5
KE - Kenya 5
NG - Nigeria 5
PY - Paraguay 5
DK - Danimarca 4
HN - Honduras 4
HR - Croazia 4
IL - Israele 4
AL - Albania 3
AZ - Azerbaigian 3
LT - Lituania 3
TN - Tunisia 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
NO - Norvegia 2
PS - Palestinian Territory 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BH - Bahrain 1
BZ - Belize 1
CW - ???statistics.table.value.countryCode.CW??? 1
ET - Etiopia 1
EU - Europa 1
GI - Gibilterra 1
GP - Guadalupe 1
GT - Guatemala 1
GY - Guiana 1
HU - Ungheria 1
KG - Kirghizistan 1
KI - Kiribati 1
KW - Kuwait 1
KZ - Kazakistan 1
LY - Libia 1
MC - Monaco 1
ML - Mali 1
MM - Myanmar 1
PA - Panama 1
RS - Serbia 1
SI - Slovenia 1
Totale 17.723
Salva come PNG Salva come JPEG
Città #
Singapore 1.473
Southend 1.055
Fairfield 942
Santa Clara 675
Ashburn 598
Hong Kong 438
Woodbridge 403
Chandler 393
Seattle 387
Wilmington 382
Hefei 377
Houston 367
Cambridge 324
Princeton 309
Dong Ket 267
Beijing 225
Ann Arbor 206
Boardman 188
Dublin 169
Seoul 161
Jacksonville 122
Ho Chi Minh City 118
Nanjing 117
Westminster 114
Padova 99
Berlin 93
Bologna 90
Dallas 86
Los Angeles 85
Hanoi 76
Tokyo 74
Jinan 69
San Diego 64
Buffalo 62
Redondo Beach 62
Shenyang 62
Turin 59
Abidjan 52
Saint Petersburg 52
Milan 45
Munich 43
Changsha 40
Hebei 40
Dearborn 39
Redmond 37
Bengaluru 35
Nanchang 33
Helsinki 31
Chicago 29
New York 29
Des Moines 27
São Paulo 26
Zhengzhou 26
Brussels 25
Guangzhou 25
Mülheim 25
Frankfurt am Main 23
Hangzhou 22
Rome 22
Tianjin 22
Shanghai 21
The Dalles 21
Falls Church 20
Jakarta 20
Al Mansurah 19
Amman 18
Bühl 18
Jiaxing 18
London 18
Moscow 18
Nuremberg 18
Vienna 18
Da Nang 17
Norwalk 17
Olalla 17
Bern 16
Fuzhou 15
Mahé 15
Montreal 15
Taiyuan 15
Biên Hòa 14
Lomé 14
Yubileyny 14
Bremen 13
Brooklyn 13
Cesena 13
Haikou 13
Lanzhou 13
Mexico City 12
Taizhou 12
Washington 12
Baghdad 11
Brisbane 11
Can Tho 11
San Venanzo 11
Sydney 11
Warsaw 11
Belo Horizonte 10
Cebu City 10
Falkenstein 10
Totale 12.132
Salva come PNG Salva come JPEG
Nome #
D-dimer in diagnosis and prevention of venous thrombosis: recent advances and their practical implications 401
A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). 276
Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. 192
Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis 188
Diagnostic Accuracy of a New d -Dimer Assay (Sclavo Auto d -Dimer) for Exclusion of Deep Vein Thrombosis in Symptomatic Outpatients 181
Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal. 178
Age and gender specific cut-off values to improve the performance of D: -dimer assays to predict the risk of venous thromboembolism recurrence. 172
D-Dimer testing for predictive recurrence risk in venous thromboembolism: looking for a useful threshold: reply to a rebuttal. 165
Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. 162
Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study 158
D-dimer for the diagnosis of upper extremity deep and superficial venous thrombosis 156
Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the DULCIS study 152
Review: recombinant factor VIIa does not differ from placebo for prevention or treatment of bleeding in patients without hemophilia 149
Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register 147
Enhancing stroke risk prediction in patients with transient ischemic attack: insights from a prospective cohort study implementing fast-track care 146
D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. 145
High plasma levels of factor VIII and risk of recurrence of venous thromboembolism 145
Diagnosis of deep vein thrombosis. 143
D-dimer and residual vein obstruction as risk factors for recurrence during and after anticoagulation withdrawal in patients with a first episode of provoked deep-vein thrombosis. 143
Inherited and acquired thrombophilic alterations in patients with superficial vein thrombosis of lower limbs 143
Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients 143
Current management strategies and long-term clinical outcomes of upper extremity venous thrombosis 142
Anticoagulant therapy for symptomatic calf deep vein thrombosis 142
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study 142
Evaluation of a chemiluminescent immunoassay, the HemosIL AcuStar D-Dimer, in outpatients with clinically suspected deep venous thrombosis 140
Evolution of untreated calf deep-vein thrombosis in high risk symptomatic outpatients: the blind, prospective CALTHRO study. 139
Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study 138
D-dimer, FVIII and thrombotic burden in the acute phase of deep vein thrombosis in relation to the risk of post-thrombotic syndrome 136
Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study. 135
The incidence of heparin-induced thrombocytopenia in patients treated with low molecular weight heparin for superficial vein thrombosis 134
External validation of the DASH prediction rule: a retrospective cohort study 134
Age‐adjusted D‐dimer, clinical pre‐test probability‐adjusted D‐dimer, and whole leg ultrasound in ruling out suspected proximal and calf deep venous thrombosis 132
Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. 132
Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH 132
D-dimer use for deep venous thrombosis exclusion in elderly patients: a comparative analysis of three different approaches to establish cut-off values for an assay with results expressed in D-dimer units 131
Thrombotic burden, D-dimer levels and complete compression ultrasound for diagnosis of acute symptomatic deep vein thrombosis of the lower limbs. 130
Sex, age and normal post-anticoagulation D-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension. 130
Rivaroxaban in the Treatment of Heparin-Induced Thrombocytopenia 130
Thrombin generation and intracranial atherosclerotic disease in patients with a transient ischaemic attack 130
Predicting the risk of recurrence of venous thromboembolism. 129
A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms 129
Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk of venous thrombosis. 128
Measurement of factor XIII (FXIII) activity by an automatic ammonia release assay using iodoacetamide blank-procedure: no more overestimation in the low activity range and better detection of severe FXIII deficiencies 128
The prothrombin time/international normalized ratio (PT/INR) Line: derivation of local INR with commercial thromboplastins and coagulometers--two independent studies. 127
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations 127
Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. 126
D-dimer testing and recurrent venous thromboembolism after unprovoked pulmonary embolism: A post-hoc analysis of the Prolong extension study. 126
Is there a role for intervention radiology for the treatment of lower limb deep vein thrombosis in the era of direct oral anticoagulants? A comprehensive review 126
Malattia tromboembolica polmonare 125
Objectives and methodology: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 124
Ultrasound Characteristics of Calf Deep Vein Thrombosis and Residual Vein Obstruction After Low Molecular Weight Heparin Treatment 124
D-dimer and reduced dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study. 123
An update on the pharmaceutical management of thrombosis 123
Assessment of the risk of bleeding in patients undergoing surgery or invasive procedures: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 123
Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication 122
D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. 121
D-dimer, oral anticoagulation, and venous thromboembolism recurrence 119
Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial. 119
Accuracy of a portable prothrombin time monitor (Coagucheck) in patients on chronic oral anticoagulant therapy: A prospective multicenter study 119
Padua Prediction Score and Hospital-Acquired Proximal and Isolated Distal Deep Vein Thrombosis in Symptomatic Patients 117
ACP Journal Club. Review: Low-molecular-weight heparin reduces risk for venous thromboembolism in adults with leg immobilization. 117
The influence of VKORC1 3730 G > A polymorphism on warfarin dose: reply. 117
High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. 117
Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study. 116
Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). 115
Update on the predictive value of D-dimer in patients with idiopathic venous thromboembolism. 113
Is there a role for oral anticoagulant therapy in patients with peripheral arterial disease? 113
The negative predictive value of D-dimer on the risk of recurrent venous thromboembolism in patients with multiple previous events: A prospective cohort study (the PROLONG PLUS study). 112
Incidence and clinical outcomes of heparin-induced thrombocytopenia: 11 year experience in a tertiary care university hospital 111
Extended treatment for venous thromboembolism: how long is long enough? 111
ARC-1779, a PEGylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent. 111
Residual vein thrombosis and serial D-dimer for the long-term management of patients with deep venous thrombosis 111
Additive thrombin inhibition by fast moving heparin and dermatan sulfate explains the anticoagulant effect of sulodexide, a natural mixture of glycosaminoglycans 111
Whole-Arm Ultrasound for Suspected Upper-Extremity Deep Venous Thrombosis in Outpatients Reply 110
Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. 110
Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therap 110
Current management of heparin-induced thrombocytopenia 110
Risks factors for highly unstable response to oral anticoagulation: a case-control study. 109
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study 108
Heparin-induced thrombocytopenia: new insights into the immune response 108
Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels. 108
Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. 107
Value of D-dimer testing to decide duration of anticoagulation after deep vein thrombosis: yes. 107
Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19 106
Risk of early recurrent fetal loss and levels of thrombin-activatable fibrinolysis inhibitor. 106
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study 106
Residual emboli on lung perfusion scan or multidetector computed tomography after a first episode of acute pulmonary embolism. 105
Whole-Arm Ultrasound to Rule Out Suspected Upper-Extremity Deep Venous Thrombosis in Outpatients 105
The Wells rule and D-dimer for the diagnosis of isolated distal deep vein thrombosis 104
Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants 104
Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of a portable prothrombin time monitor (COAGUCHECK) 104
D-dimer testing to determine the duration of anticoagulation therapy. 103
The influence of factor V Leiden and G20210A prothrombin mutation on the presence of residual vein obstruction after idiopathic deep-vein thrombosis of the lower limbs 103
Duration of anticoagulation after isolated pulmonary embolism 103
Presence of residual thromboemboli at least six months after a first episode of symptomatic pulmonary embolism: do perfusion scintigraphy and angio-computed tomography agree? 101
Platelet RNA sequencing for cancer screening in patients with unprovoked venous thromboembolism: a prospective cohort study 100
Capsular Warning Syndrome: Features, Risk Profile, and Prognosis in a Large Prospective TIA Cohort 100
Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum) 100
Management of idiopathic venous thromboembolism 100
Monitoring patients with the lupus anticoagulant while treated with vitamin K antagonists: communication from the SSC of the ISTH 100
Totale 13.031
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.071
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.071
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.009 0 0 0 0 0 50 40 111 251 81 74 402
2021/20222.051 205 95 177 116 246 111 63 207 87 97 289 358
2022/20232.016 261 281 117 275 111 162 59 116 283 93 172 86
2023/2024431 36 97 44 30 28 20 20 35 19 41 27 34
2024/20253.643 82 537 168 229 947 176 247 49 106 236 181 685
2025/20264.097 534 774 786 554 1.066 383 0 0 0 0 0 0
Totale 18.123